Short interest ratio: 32 Insider Buying: $1.2 million Biopharmaceutical company Telik Inc. said recently reported that its third-quarter loss widened as the company recorded costs for stock-based compensation.

Short interest ratio: 17 Insider buying: $27.8 million Valeant Pharmaceuticals announced in early November that the company wouldn't release full third-quarter financial data until it completes an investigation of its stock-options practices.

Short interest ratio: 21 Insider buying: $77.2 million Tercica, Inc., a development stage biopharmaceutical company announced in erarly November that its Q3 net loss widened.

Short interest ratio: 15 Insider buying: $14.8 million GenTek, Inc, which engages in the manufacture and marketing of industrial components and performance chemicals reported Q3 operating profit improved 70% on 11-9-2006.

Short interest ratio: 25 Insider buying: $6.1 million PokerTek Inc., which makes electronic poker tables, will announce earnings this monday, November 13th.

Short interest ratio: 23 Insider buying: $5.3 million In late October 2006, Consolidated-Tomoko Land Co., a developer of Florida real estate, said third-quarter earnings fell 9 percent, hurt by reduced stock-option expense accruals recorded in 2005.

Short interest ratio: 23 Insider buying: $4.3 million Gehl Co., which makes light-construction and agricultural equipment, announced on 10-31-06 a 65 percent increase in third-quarter earnings, boosted by international sales.

Short interest ratio: 23 Insider buying: $3.8 million Metabasis Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases.